An international, randomized, placebo‐controlled, phase 2b clinical trial of intepirdine for dementia with Lewy bodies (HEADWAY‐DLB)

INTRODUCTION: A phase 2b clinical trial, HEADWAY‐DLB, was performed to assess treatment with intepirdine, a serotonin receptor antagonist, in patients with dementia with Lewy bodies (DLB). METHODS: HEADWAY‐DLB was a multinational, double‐blind, randomized, placebo‐controlled study. Two hundred sixty...

Descripción completa

Detalles Bibliográficos
Autores principales: Lang, Frederick M., Kwon, Daniel Y., Aarsland, Dag, Boeve, Brad, Tousi, Babak, Harnett, Mark, Mo, Yi, Noel Sabbagh, Marwan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8215076/
https://www.ncbi.nlm.nih.gov/pubmed/34189249
http://dx.doi.org/10.1002/trc2.12171

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8215076/
https://www.ncbi.nlm.nih.gov/pubmed/34189249
http://dx.doi.org/10.1002/trc2.12171

Ejemplares similares